FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2126840220> ?p ?o ?g. }

• W2126840220 abstract "Hematocrit falls after birth in preterm infants due to physiological factors and blood letting. Low plasma levels of erythropoietin (EPO) in preterm infants provide a rationale for the use of EPO to prevent or treat anemia.To assess the effectiveness and safety of late initiation of EPO (initiated at 8 days after birth or later) in reducing the use of red blood cell transfusions in preterm and/or low birth weight infants.Subgroup analyses of low (< 500 IU/kg/week) and high (> 500 IU/kg/week) doses of EPO and within these subgroups analyses of the use of low (< 5 mg/kg/day) and high (> 5 mg/kg/day) doses of supplemental iron, in reducing the use of red blood cell transfusions in these infants.MEDLINE, EMBASE, CINAHL, abstracts from scientific meetings published in Pediatric Research and reference lists of identified trials and reviews were searched in November 2005/April 2006 and the Cochrane Central Register of Controlled Trials (CENTRAL, The Cochrane Library, Issue 2, 2006). No language restrictions were applied.Randomised or quasi-randomized controlled trials of late initiation of EPO treatment (started at eight days of age or later) vs. placebo or no intervention in preterm (< 37 weeks) and/or low birth weight (< 2500 g) neonates. For inclusion the studies needed to provide information on at least one outcome of interest.Data were abstracted by the two authors on pre-tested data collection forms. Data were entered by one review author (AO) and checked for accuracy by the other (SA). Data were analysed using RevMan 4.2.8. The statistical methods included relative risk (RR), risk difference (RD), number needed to treat to benefit (NNTB), number needed to treat to harm (NNTH) for dichotomous outcomes and weighted mean difference (WMD) for continuous outcomes reported with their 95% confidence intervals (CI). A fixed effects model was used for meta-analyses. Heterogeneity tests including the I squared (I(2)) statistic were performed to assess the appropriateness of pooling the data.Twenty-eight studies enrolling 1302 preterm infants in 21 countries were included. The quality of the trials varied. Most trials were of small sample size. Only one study clearly stated that infants were excluded if they had received red blood cell transfusion prior to study entry (Samanci 1996). A total of 19 studies including 912 infants reported on the primary outcome of Use of one or more red cell transfusions. The meta-analysis showed a significant effect [typical RR; 0.66 (95% CI; 0.59, 0.74); typical RD -0.21 (95% CI; -0.26, -0.16); typical NNTB of 5 (95% CI 4, 6)]. There was statistically significant heterogeneity [for RR (p < 0.00001), I(2 )= 74.0% and for RD (p = 0.0006), I(2 )=58.9%]. Similar results were obtained in secondary analyses based on different combinations of high/low doses of EPO and iron supplementation. There was a significant reduction in the total volume (ml/kg) of blood transfused per infant (four studies enrolling 177 infants) [typical WMD = -7 ml (95% CI -12, -3)] and in the number of transfusions per infant (nine studies enrolling 567 infants); [typical WMD -0.78 (-0.97, -0.59)]. The effect size was less in a post hoc analyses of high quality studies compared to studies in which the quality was uncertain and in studies that used strict guidelines for red blood cell transfusions vs. studies that did not. There were no significant differences in mortality, retinopathy of prematurity, sepsis, intraventricular haemorrhage, periventricular leukomalacia, necrotizing enterocolitis, bronchopulmonary dysplasia, SIDS, neutropenia, hypertension, or length of hospital stay. Long-term neurodevelopmental outcomes were not reported.Late administration of EPO reduces the use of one or more red blood cell transfusions, the number of red blood cell transfusions per infant and the total volume of red blood cell transfused per infant. The clinical importance of the results for the latter two outcomes is marginal (< 1 transfusion per infant and 7 ml/kg of transfused red blood cells). Any donor exposure is likely not avoided as most studies included infants who had received red cell transfusions prior to trial entry. Late EPO does not significantly reduce or increase any of many important neonatal adverse outcomes including mortality and retinopathy of prematurity. Further research of the use of late EPO treatment to prevent donor exposure is not indicated. Research efforts should focus on limiting donor exposure during the first few days of life in sick neonates, when red blood cell requirements are most likely to be required and cannot be prevented by late EPO treatment." @default.
• W2126840220 created "2016-06-24" @default.
• W2126840220 creator A5009402234 @default.
• W2126840220 creator A5046655310 @default.
• W2126840220 date "2014-04-23" @default.
• W2126840220 modified "2023-10-18" @default.
• W2126840220 title "Late erythropoietin for preventing red blood cell transfusion in preterm and/or low birth weight infants" @default.
• W2126840220 cites W113731524 @default.
• W2126840220 cites W130943047 @default.
• W2126840220 cites W1538983550 @default.
• W2126840220 cites W1576188136 @default.
• W2126840220 cites W1579188693 @default.
• W2126840220 cites W1955846879 @default.
• W2126840220 cites W1965134002 @default.
• W2126840220 cites W1966298541 @default.
• W2126840220 cites W1967987482 @default.
• W2126840220 cites W1970849149 @default.
• W2126840220 cites W1979409966 @default.
• W2126840220 cites W1980482563 @default.
• W2126840220 cites W1980704721 @default.
• W2126840220 cites W1983674089 @default.
• W2126840220 cites W1991223936 @default.
• W2126840220 cites W1991505056 @default.
• W2126840220 cites W1996560509 @default.
• W2126840220 cites W1997559766 @default.
• W2126840220 cites W2000096309 @default.
• W2126840220 cites W2003192408 @default.
• W2126840220 cites W2013412830 @default.
• W2126840220 cites W2014701423 @default.
• W2126840220 cites W2017516586 @default.
• W2126840220 cites W2017801082 @default.
• W2126840220 cites W2020701166 @default.
• W2126840220 cites W2025146225 @default.
• W2126840220 cites W2030460496 @default.
• W2126840220 cites W2030768012 @default.
• W2126840220 cites W2032984731 @default.
• W2126840220 cites W2037007129 @default.
• W2126840220 cites W2044703217 @default.
• W2126840220 cites W2052107678 @default.
• W2126840220 cites W2053816871 @default.
• W2126840220 cites W2054737653 @default.
• W2126840220 cites W2056285559 @default.
• W2126840220 cites W2057715044 @default.
• W2126840220 cites W2058065351 @default.
• W2126840220 cites W2067406412 @default.
• W2126840220 cites W2068288976 @default.
• W2126840220 cites W2076369332 @default.
• W2126840220 cites W2080684014 @default.
• W2126840220 cites W2087221601 @default.
• W2126840220 cites W2094104875 @default.
• W2126840220 cites W2099472583 @default.
• W2126840220 cites W2119156236 @default.
• W2126840220 cites W2125435699 @default.
• W2126840220 cites W2129745399 @default.
• W2126840220 cites W2136846885 @default.
• W2126840220 cites W2137199928 @default.
• W2126840220 cites W2139350161 @default.
• W2126840220 cites W2150717656 @default.
• W2126840220 cites W2157978179 @default.
• W2126840220 cites W2157988632 @default.
• W2126840220 cites W2169272691 @default.
• W2126840220 cites W2171065076 @default.
• W2126840220 cites W2177544070 @default.
• W2126840220 cites W2409536750 @default.
• W2126840220 cites W4214559180 @default.
• W2126840220 cites W4236998227 @default.
• W2126840220 cites W4239867950 @default.
• W2126840220 cites W4243635555 @default.
• W2126840220 cites W4245395387 @default.
• W2126840220 cites W4245448789 @default.
• W2126840220 cites W4319308506 @default.
• W2126840220 cites W66883936 @default.
• W2126840220 cites W2024090069 @default.
• W2126840220 doi "https://doi.org/10.1002/14651858.cd004868.pub4" @default.
• W2126840220 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24760628" @default.
• W2126840220 hasPublicationYear "2014" @default.
• W2126840220 type Work @default.
• W2126840220 sameAs 2126840220 @default.
• W2126840220 citedByCount "68" @default.
• W2126840220 countsByYear W21268402202012 @default.
• W2126840220 countsByYear W21268402202013 @default.
• W2126840220 countsByYear W21268402202014 @default.
• W2126840220 countsByYear W21268402202015 @default.
• W2126840220 countsByYear W21268402202016 @default.
• W2126840220 countsByYear W21268402202017 @default.
• W2126840220 countsByYear W21268402202018 @default.
• W2126840220 countsByYear W21268402202019 @default.
• W2126840220 countsByYear W21268402202020 @default.
• W2126840220 countsByYear W21268402202021 @default.
• W2126840220 crossrefType "journal-article" @default.
• W2126840220 hasAuthorship W2126840220A5009402234 @default.
• W2126840220 hasAuthorship W2126840220A5046655310 @default.
• W2126840220 hasConcept C126322002 @default.
• W2126840220 hasConcept C142724271 @default.
• W2126840220 hasConcept C168563851 @default.
• W2126840220 hasConcept C187212893 @default.
• W2126840220 hasConcept C204787440 @default.
• W2126840220 hasConcept C27081682 @default.
• W2126840220 hasConcept C2776478404 @default.
• W2126840220 hasConcept C2778248108 @default.

• next